IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

AGENO, WALTER
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 56.212
EU - Europa 25.430
AS - Asia 18.427
SA - Sud America 2.081
AF - Africa 339
Continente sconosciuto - Info sul continente non disponibili 56
OC - Oceania 27
Totale 102.572
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 55.676
IT - Italia 11.854
SG - Singapore 6.084
UA - Ucraina 4.101
CN - Cina 3.661
TR - Turchia 2.849
VN - Vietnam 2.473
HK - Hong Kong 2.164
DE - Germania 1.853
SE - Svezia 1.850
BR - Brasile 1.741
IE - Irlanda 1.239
GB - Regno Unito 1.032
FR - Francia 994
FI - Finlandia 975
RU - Federazione Russa 861
IN - India 292
BD - Bangladesh 257
MX - Messico 233
CA - Canada 230
AR - Argentina 119
NL - Olanda 115
JP - Giappone 113
AT - Austria 108
NG - Nigeria 98
IQ - Iraq 95
ES - Italia 92
PL - Polonia 92
ZA - Sudafrica 82
EC - Ecuador 55
EU - Europa 53
PK - Pakistan 51
SA - Arabia Saudita 50
BE - Belgio 46
ID - Indonesia 41
UZ - Uzbekistan 39
CO - Colombia 37
AE - Emirati Arabi Uniti 34
CZ - Repubblica Ceca 34
MA - Marocco 34
VE - Venezuela 34
LT - Lituania 30
MY - Malesia 30
CL - Cile 28
EG - Egitto 24
JO - Giordania 23
KE - Kenya 23
PY - Paraguay 23
PH - Filippine 22
AU - Australia 21
CH - Svizzera 21
DZ - Algeria 19
RO - Romania 18
TN - Tunisia 17
MD - Moldavia 16
BO - Bolivia 15
JM - Giamaica 15
PT - Portogallo 15
TW - Taiwan 15
UY - Uruguay 15
NP - Nepal 14
KR - Corea 12
PE - Perù 12
GR - Grecia 11
IL - Israele 11
IR - Iran 11
AL - Albania 10
CR - Costa Rica 10
KZ - Kazakistan 10
TT - Trinidad e Tobago 10
LB - Libano 9
PS - Palestinian Territory 9
HU - Ungheria 8
OM - Oman 8
SN - Senegal 8
AZ - Azerbaigian 7
DK - Danimarca 7
MK - Macedonia 7
NI - Nicaragua 7
NO - Norvegia 7
BG - Bulgaria 6
CI - Costa d'Avorio 6
RS - Serbia 6
DO - Repubblica Dominicana 5
ET - Etiopia 5
GT - Guatemala 5
NZ - Nuova Zelanda 5
QA - Qatar 5
TH - Thailandia 5
AM - Armenia 4
AO - Angola 4
BA - Bosnia-Erzegovina 4
BS - Bahamas 4
GE - Georgia 4
HN - Honduras 4
HR - Croazia 4
LK - Sri Lanka 4
PA - Panama 4
BB - Barbados 3
BN - Brunei Darussalam 3
Totale 102.509
Salva come PNG Salva come JPEG
Città #
Milan 8.529
Fairfield 7.198
Woodbridge 4.800
Ashburn 4.583
San Jose 3.848
Houston 3.563
Jacksonville 3.304
Singapore 3.198
Seattle 2.805
Wilmington 2.632
Cambridge 2.460
Ann Arbor 2.425
Chandler 2.237
Hong Kong 2.131
Dallas 1.559
Izmir 1.397
Princeton 1.350
Dublin 1.229
The Dalles 985
Dearborn 961
Boardman 832
Beijing 683
Dong Ket 683
Nyköping 664
Rome 641
Lauterbourg 639
Chicago 637
Council Bluffs 546
San Diego 399
Ho Chi Minh City 393
Los Angeles 353
New York 330
San Mateo 308
Ogden 261
London 260
Santa Clara 256
Hanoi 241
Helsinki 228
Como 190
Guangzhou 184
São Paulo 179
Washington 168
Munich 153
Mexico City 150
Düsseldorf 139
Orem 132
Hefei 129
Redmond 122
Nanjing 106
Nuremberg 97
Tokyo 97
Abuja 92
Shanghai 90
Frankfurt am Main 88
Kocaeli 88
Kunming 84
Verona 84
Chennai 83
Phoenix 77
Norwalk 75
Warsaw 75
Hangzhou 74
Brooklyn 72
Salt Lake City 72
Montreal 71
Buffalo 68
San Francisco 65
Tianjin 64
Shenzhen 61
Stockholm 59
Amsterdam 58
Jinan 58
Nanchang 57
Haiphong 56
Atlanta 55
Columbus 55
Toronto 55
Turku 55
Boston 54
Denver 53
Rio de Janeiro 53
Manchester 51
Da Nang 50
Tampa 49
Elk Grove Village 46
Philadelphia 46
Zhengzhou 46
Belo Horizonte 45
Johannesburg 45
Vienna 44
Kilburn 39
Brussels 38
Falls Church 38
Fuzhou 35
Tashkent 34
Besana In Brianza 33
Changsha 32
Mumbai 32
Wuhan 31
Curitiba 30
Totale 74.209
Salva come PNG Salva come JPEG
Nome #
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: a Delphi analysis of experts 403
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery 312
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes 312
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study 302
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis 301
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 294
Abdominal obesity and the risk of recurrent deep vein thrombosis 271
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature 269
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients 268
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment 267
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 265
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 263
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review 262
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 257
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry 257
Risk of recurrence of unusual site venous thromboembolism 256
ABO blood group and vascular disease: an update 253
Optimal treatment duration of venous thrombosis 250
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism 247
Management of recurrent venous thromboembolism in cancer patients 247
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature 246
Breadth of complications of long-term oral anticoagulant care 246
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal 244
Warfarin interactions with antibiotics in the ambulatory care setting 240
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. 237
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients 234
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study 234
Prevention and treatment of venous thromboembolism 232
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 231
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. 230
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data 230
A new era for venous thromboembolism prevention in medical inpatients 230
Exaggerated initial response to warfarin following heart valve replacement 229
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice 229
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome 229
Venous ischemic syndromes 229
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial 228
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study 228
Oral rivaroxaban for symptomatic venous thromboembolism 225
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. 225
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy 224
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 222
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis 222
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty 221
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism 221
A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment 221
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis 220
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 218
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis 218
Applying EBM in clinical practice 217
Patient selection for thromboprophylaxis in medical inpatients 217
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study 217
A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. 216
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 216
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review 216
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study 215
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants 214
Venous and arterial thrombosis in patients with HIV infection 213
Abdominal obesity and the risk of recurrent deep vein thrombosis. 212
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study 212
Statins, fibrates, and venous thromboembolism: a meta-analysis. 212
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis 212
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure” 212
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study 212
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients 211
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature 211
Duration of anticoagulation after venous thromboembolism in real world clinical practice 210
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation 210
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? 209
Management of incidental splanchnic vein thrombosis in cancer patients 209
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study 209
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications 209
A survey of thromboprophylaxis management in patients with major trauma. 208
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism. 208
Venous thromboembolism: Past, present and future 208
Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature 208
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin? 208
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study 207
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study 206
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study 206
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study 206
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature 205
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation 205
Acute myeloid leukemia with associated translocation t(15;17) and 11q23/MLL abnormality 204
Managing challenging patients with venous thromboembolism: A practical, case-based approach 204
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 203
Guidance for the management of venous thrombosis in unusual sites 202
Direct oral anticoagulants in rare venous thrombosis 202
Treating patients with cancer and acute venous thromboembolism 201
Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. 199
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes 199
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation 199
Statins and secondary prevention of ischemic and hemorrhagic stroke 198
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal 198
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE 198
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage 198
Dabigatran in clinical practice: Contemporary overview of the evidence 198
Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study 198
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians 198
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. 197
Totale 22.761
Salva come PNG Salva come JPEG
Categoria #
all - tutte 437.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 437.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.597 0 0 0 0 0 0 0 0 0 0 0 1.597
2021/20226.828 757 872 355 182 402 376 337 375 386 1.267 644 875
2022/20236.740 824 258 431 650 510 1.571 19 787 1.024 268 191 207
2023/202413.559 2.152 2.188 2.195 2.612 2.767 824 95 147 391 79 37 72
2024/20259.742 69 75 1.781 238 230 684 403 654 1.099 820 967 2.722
2025/202623.123 1.428 1.409 1.478 2.721 1.762 1.425 5.181 1.401 2.969 1.581 1.099 669
Totale 103.466